Phase 2 N=16 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study
Diabetic Foot Ulcer · Offloading
Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
N/A N=84 Plantar Heel Pain: Multisegment Foot Motion and Muscle Function, FFI Translation, and Evaluation of Treatments
Plantar Fasciitis
Primary: Worst Pain — 5.96; 5.74; 3.91; 4.08 score — p=0.660
N/A N=1,633 Silicone Adhesive Multilayer Foam Dressings to Prevent Pressure Ulcer
Pressure Ulcer
Primary: Number of Participants Who Developed a New Pressure Ulcer Category 2 or Worse on Sacrum, Heels or Greater Trochanter — 43; 34 Participants — p=0.04
Phase 4 N=82 Study of Oasis Ultra in Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: Percentage of Wounds Closed — 54; 32 percentage of wounds closed
N/A N=85 Effectiveness of Core Stability Exercises on Foot Posture, Function and Limb Alignment in Flexible Flat Feet Patients
Flexible Flatfoot
Primary: Staheli Plantar Arch Index (SPAI) — -0.18; -0.03; -0.138; -0.036 Millimeters (mm) — p=<0.001
Phase 2 N=20 Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
Diabetic Neuropathic Arthropathy
Primary: SUV Max on PET/CT Scan at 12 Months — 26.1; 22.9 g/ml
N/A N=15 Effects of Different Support Surfaces on the Properties Skin After Loading
Pressure Ulcers
Primary: Transepidermal Water Loss (TEWL) in g/m2/h on Sacrum, at Baseline — 7.8; 7.7; 7.1 g/m2/h
N/A N=900 Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
Diabetic Retinopathy · Diabetic Eye Problems · Diabetic Macular Edema
Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives
Phase 3 N=48 Beta Adrenergic Antagonist for the Healing of Chronic DFU
Chronic Diabetic Foot Ulcers · Diabetic Neuropathic Ulcers · Non Healing Wound
Primary: Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period — 8; 7 Participants
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
N/A N=29 A Personalized Self-care Support Program for Primary Care Patients With Diabetic Foot Ulcer
Foot Ulcer
Primary: Feasibility of Recruiting and Retaining — 26 Participants
Phase 4 N=102 Use of Santyl in Diabetic Foot Ulcers
Diabetic Foot · Foot Ulcer, Diabetic
Primary: Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment. — 57.6; 41.3 percentage of change from baseline (cm2)
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm
Phase 3 N=130 Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients